On Demand 2020 Friday General Sessions

This collection covers general sessions from Friday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Guiding Patients Through Peanut Immunotherapy Options
  • COVID-19 and Its Impact on Our World, Our Patients and Ourselves  
  • Addressing Racial and Ethnic Health Disparities in Allergy/Immunology Populations
  • Approach To Diagnosis And Management Of Nasal Polyps In The Biologic Era
  • Hot Topics in Immunotherapy
  • Vaccines: The Good, The Bad and The Scary

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 8.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Discuss how to use shared decision-making to help patients and allergists understand treatment options and help allergists understand what their patients value
  • Discuss non-FDA-approved oral immunotherapy
  • Discuss FDA-approved immunotherapy, epicutaneous immunotherapy, and ongoing avoidance without treatment. Use shared decision-making to guide patients through the options
  • Anticipate common sources of misinformation that impact medical decision making among our patients
  • Counsel patients regarding risk factors associated with more severe COVID-19 infection
  • Identify signs of stress and anxiety and how that impacts overall health
  • Describe the racial and ethnic disparities in food allergy, atopic dermatitis and asthma
  • Understand effective ways to address disparities in caring for the patient with allergic or immunologic disease
  • Detail the gaps in research regarding disparities in food allergy, asthma and atopic dermatitis
  • Understand the endotypes of chronic sinusitis with nasal polyps and practical approaches to identifying these variations in clinical practice
  • Develop a comprehensive diagnostic and therapeutic approach to nasal polyps with updates in medical and surgical management
  • Discuss the use of biologics in nasal polyps based on disease mechanism of individual phenotypes
  • Understand the rationale for allergen standardization
  • Describe the risk factors associated with anaphylaxis from immunotherapy and evidence supporting or refuting epinephrine auto-injectors for all patients receiving SCIT
  • Understand the risks, benefits and indications for using various build-up schedules
  • Understand how outbreaks of preventable diseases develop and how we can help prevent them
  • Recognize vaccine-related adverse effects, including allergic reactions, and how to evaluate and manage them
  • Using the recent coronavirus outbreak as an example, disseminate information on challenges involved in how vaccines are developed, studied and released for public use.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, and/ or evaluation relevant to a CME activity. Disclosed information is reviewed in advance in order to manage and resolve any potential conflicts of interest. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations.

Specific disclosure information for the 2020 Annual Meeting is available online and via the meeting app.

Course summary
Available credit: 
  • 8.50 AMA PRA Category 1 Credit™
  • 8.50 Attendance
  • 8.50 CBRN
Course opens: 
11/17/2020
Course expires: 
11/29/2023
Rating: 
0

David R. Stukus, MD, FACAAI
David M. Fleischer, MD, FACAAI
Arnon Elizur, MD
Edwin H. Kim, MD, FACAAI
Julie Wang, MD, FACAAI
Jay A. Lieberman, MD, FACAAI
Matthew C. Greenhawt, MD, MSc, MBA, FACAAI
Brian T. Kelly, MD, MA, FACAAI
Timothy Caulfield, LLM, FRSC, FCAHS
Brian Lipworth, MD, FACAAI
Jessi Gold, MD, MS
Jonathan Silverberg, MD, PhD, MPH
Tamara T. Perry, MD
Carla Davis, MD, FACAAI
John B. Hagan, MD, FACAAI
Puneet Shroff, MD, FACAAI
Sandra Y. Lin, MD
Joshua Levy, MD
Merin E. Kuruvilla, MD
Ellen R. Sher MD, FACAAI
Peter J. Mustillo, MD, FACAAI
Harold S. Nelson, MD, FACAAI 
David I. Bernstein, MD, FACAAI 
Jay M. Portnoy, MD, FACAAI
Melinda M. Rathkopf, MD, FACAAI
Mervat Nassef, MD, FACAAI
Lisa Saiman, MD, MPH 
John M. Kelso, MD, FACAAI
Julie E. Ledgerwood, DO

Available Credit

  • 8.50 AMA PRA Category 1 Credit™
  • 8.50 Attendance
  • 8.50 CBRN
Please login or create an account to take this course.